Translate page

-- Virtual Education Program: 2019 Edition


Presentations from the COLT Meeting 2019

We are pleased to make available a series of presentations from the COLT Meeting 2019, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, management of CML, practicalities and monitoring TFR and Ph+ALL.

Timothy Hughes

David Yeung 3 Devendra Hiwase

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • Frontline Therapy for CML 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)



Timothy Hughes



Frontline Therapy for CML
Prof. Tim Hughes, SAHMRI / University of Adelaide

  • Consensus and controversies  in frontline therapy for CML
  • Relative risk of CML patients according to clinical and haematological data at diagnosis
  • Heterogeneity of response to TKI therapy in CML
  • Risk-adapted/goal specific treatment schema
  • Frontline therapy selection
  • Results from the TIDEL II trial in Australia/NZ
  • Future of CML management: Bioassay and molecular dynamics driven
  • Conclusions


David Yeung 3  

When frontline therapy fails
Dr David Yeung - SAHMRI / Royal Adelaide Hospital

  • LASOR/DASCERN - failure to achieve 2019 ELN goals
  • TIDEL II - failure to achieve optimal ELN 2013 treatment goals
  • ENESTCmr - failure to achieve deep molecular response
  • Ponatinib - drug of last resort
  • Asciminib (ABL001) - rising star?

Devendra Hiwase


CML - Beyond chronic phase
Dr Devendra Hiwase - SA Pathology / Royal Adelaide Hospital

  • Diagnostic and management issues in CML-AP
    • Definitions of accelerated phase
    • Staging of chronic myeloid leukemia in the imatinib era
    • Survival benefit with Imatinib in CML-AP
    • Study results on NIL and DAS in patients with CML-AP
    • Imatinib vs. allogeneic SCT in CML-AP patients
    • Treatment strategy recommendations for CML-AP
    • Patient case
  • Diagnostic criteria and management of blast crisis
    • Transformation to blast crisis
    • Survival of CML-BC patients: German CML studies I to IIIA
    • Outcome of blast crisis in the era of TKI therapy
    • Cytogenetic landscape and impact in blast phase of CML in the era of TKI therapy
    • Management issues in CML-BC
    • IM and 2nd generation TKI's in BC patients
    • Patient case